Provide feedbackProvide feedback

Home :: Cardiology :: Cardiology Conferences :: American Heart Association Scientific Sessions 2008

Norton AHA Coverage

American Heart Association Scientific Sessions 2008

November 8 - 12, 2008New Orleans, LA
VerusMed is an independent news organization and is not affiliated with the Norton AHA Coverage

New analysis diminishes clinically important benefit implied by conventional statistical significance of TRITON-TIMI 38 trial

Sunday, November 16, 2008 | Comments

By Patrice La Vigne

Use of the Bayesian approach to reanalyze the TRITON-TIMI 38 study reveals that the probability of a clinically important benefit was far less than what was implied by conventional statistical significance methods, researchers conclude.

...[more] Locked

Study identifies potential predictors of diabetes among patients with high CVD risk

Wednesday, November 12, 2008 | Comments

By Patrice La Vigne

Cardiovascular disease (CVD) and diabetes mellitus often occur concurrently, and while administering an oral glucose tolerance test (OGTT) to all patients with a high CVD risk would be ideal for identifying undiagnosed diabetes, Dr. Mary Angelyn ...[more] Locked

Physicians report many challenges in cardiovascular risk assessment, treatment

Wednesday, November 12, 2008 | Comments

By Patrice La Vigne

From cardiovascular risk assessment to treatment to patient adherence, physicians are challenged by the "how to," according to a panel of experts.

Dr. Donald Lloyd-Jones, associate professor of medicine at ...[more] Locked

Early catherization following MI may be better for high-risk patients, research shows; conservative strategy can be recommended for others

Wednesday, November 12, 2008 | Comments

By Patrice La Vigne

The question is no longer whether to administer cardiac catheterization following the onset of unstable angina or non-ST segment elevation myocardial infarction (non-STEMI), but whether it should be done early or later, Dr. Shamir Mehta from ...[more] Locked

Better efficacy, safety demonstrated by atorvastatin, fenofibrate fixed-dose combination relative to monotherapies

Sunday, November 16, 2008 | Comments

By Patrice La Vigne

Combination fixed-dose therapy with atorvastatin and low-dose fenofibrate may lead to greater improvements in lipid parameters relative to atorvastatin or fenofibrate alone, new evidence shows.

In the multicenter, double-blind study, ...[more] Locked

OSA identified as novel risk factor for sudden cardiac death

Sunday, November 16, 2008 | Comments

WATCH VIDEO from AHA

By Selma Kaszczuk

Obstructive sleep apnea (OSA) is an independent predictor of sudden cardiac death (SCD), Dr. Apoor Gami of Midwest Heart ...[more] Locked

Drug-eluting stents do not increase risk of death, MI relative to bare-metal stents in patients with diabetes during long-term follow-up, analysis reveals

Thursday, November 13, 2008 | Comments

By Selma Kaszczuk

Patients with diabetes who are treated with drug-eluting stents (DES) experience no increased risk of death or myocardial infarction (MI) during long-term follow-up as ...[more] Locked

Change in percent atheroma volume similar following treatment with rosiglitazone, glipizide in patients with type 2 diabetes, APPROACH data show

Sunday, November 16, 2008 | Comments

By Selma Kaszczuk

The effect of the insulin sensitizer rosiglitazone versus that of the insulin secretagogue glipizide on intravascular ultrasound (IVUS) measures of atherosclerosis in native coronary arteries among patients with type 2 diabetes do not appear to ...[more] Locked

Irbesartan does not seem to reduce death, hospitalization in patients with preserved LVEF HF, study finds

Thursday, November 13, 2008 | Comments

By Patrice La Vigne

Although angiotensin II receptor blockers are commonly used to treat heart failure (HF) in patients with preserved left ventricular ejection fraction (LVEF), there are ...[more] Locked

Oral anticoagulant rivaroxaban meets secondary, not primary, efficacy endpoint in dose-finding study, will advance to Phase III trial

Thursday, November 13, 2008 | Comments

By Selma Kaszczuk

Rivaroxaban, an oral direct factor Xa inhibitor, did not meet the primary efficacy endpoint of the ATLAS ACS-TIMI 46 trial, but results related to secondary efficacy ...[more] Locked

Safety, efficacy of interferon beta-1b for virus elimination in chronic viral cardiomyopathy confirmed in new trial

Sunday, November 16, 2008 | Comments

By Patrice La Vigne

Patients with chronic viral cardiomyopathy may receive clinical benefits safely from interferon beta-1b therapy, according to new findings.

Study researcher Dr. Heinz-Peter Schultheiss from ...[more] Locked

Improving bystander intervention, postresuscitation care, other strategies necessary to increase survival after cardiac arrest

Thursday, November 13, 2008 | Comments

By Selma Kaszczuk

Each link in the chain of events related to treating patients with cardiac arrest, from bystander intervention to postresuscitation care, plays a critical role in maximizing survival; however, there are several areas of particular importance as outlined ...[more] Locked



  1. No articles have been read
  1. No articles have been emailed
Videos